Nasus Pharma (NSRX) Stock: Buy, Sell, or Hold?
$2.87
+0.05 (+1.77%)
▲
5d:
+1.77%
30d:
-9.32%
90d:
-22.43%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (83%)
Quality Score
49/100
Position
OVERSOLD
30-Day Fair Range
$2.94 – $3.47
Position: OVERSOLD
Forward P/E & Valuation
-2.6x
Next 12M consensus est.
Wall Street Target
$16.50
+474.9% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$2.75 / $3.40
Trend: Sideways
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 MIXED SIGNALS: NSRX shows conflicting indicators. Wait for confirmation before entering.
Get Alerted When NSRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: NSRX is currently trading at $2.87, which is considered oversold relative to its 30-day fair value range of $2.94 to $3.47.
Technical Outlook: Technically, NSRX is showing sideways momentum. Immediate support is located at $2.75, while resistance sits at $3.40.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $16.50 (+474.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NSRX is showing sideways momentum. Immediate support is located at $2.75, while resistance sits at $3.40.
Market Sentiment: The stock scores a mixed 51/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $16.50 (+474.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$2.94 -
$3.47
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
Trading Range & Key Levels
30-Day Trading Range
$2.94 -
$3.47
Current vs Trading Range
OVERSOLD
Support Level
$2.75
Resistance Level
$3.40
Current Trend
Sideways
Technical data as of
Nov 13, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (51/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 474.9% below Wall St target ($16.50)
- WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-2.61
Wall Street Target
$16.50
(+474.9%)
Share NSRX Analysis
Share this live NSRX analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (NSRX)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Jun 22, 2026
Daily AI digest
AI Retail Discussion Summary:
CEO of $NSRX, Dan Benjamin, purchased 6,550 shares, boosting his total holdings to 163,541. No recent news articles available.
Key Retail Themes:
CEO buy
Insider buying
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 14, 2026 11:57 PM ET
Data refreshes hourly during market hours. Next update: 12:57 AM
Data refreshes hourly during market hours. Next update: 12:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NSRX showing a specific setup today?
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1453 | 39 SELL |
|
ABBV
AbbVie Inc |
STRONG BUY
29 analysts |
$306 | 49 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$175 | 47 HOLD |
|
MRK
Merck & Company Inc |
BUY
28 analysts |
$162 | 53 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$266 | 41 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive NSRX Research Pages